A Phase 1, Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Assess the Relative Bioavailability of Four 80 mg Febuxostat XR Formulations
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Febuxostat (Primary)
- Indications Gout; Hypertension; Hyperuricaemia; Tumour lysis syndrome
- Focus Pharmacokinetics
- Sponsors Takeda
- 11 Apr 2016 Status changed from recruiting to completed.
- 30 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 29 Jul 2015 New trial record